What does mainstream media say about enzyme replacement therapies?

Area of Science:

• Pharmacology
• Medical Communications
• Public Health Policy

Background:

• Enzyme replacement therapies (ERTs) are critical treatments for inherited diseases but face challenges with provincial funding and patient affordability.
• Media coverage is frequently utilized to advocate for ERT funding, potentially influencing patient and physician awareness.

Purpose of the Study:

• To analyze the portrayal of ERTs in Canadian print media.
• To assess the accuracy and completeness of information regarding ERT efficacy and safety in public reports.

Main Methods:

• Searched the Canadian Newsstream database for articles on three specific ERTs: Elaprase™, Naglazyme™, and Vimizim™.
• Reviewed articles for data on efficacy, adverse events, healthcare professional involvement, and information sources.
• Conducted thematic analysis on how drug efficacy was presented, comparing findings to product monographs and meta-analyses.

Main Results:

• Only 9% of articles cited clinical trial data for efficacy, and 7% mentioned adverse events.
• Physician opinions on medical necessity or efficacy were present in only 23% of articles; politicians dominated these opinions.
• Information on the underlying conditions was generally accurate but often incomplete.

Conclusions:

• Inaccurate or incomplete media reporting on ERT efficacy and safety may mislead patients and influence public pressure for drug funding.
• Physicians need to be aware of potentially misleading information patients may encounter in the media.
• Improved reporting standards are necessary to ensure informed decision-making regarding ERT access.